anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of the study is to evaluate the efficacy and safety of ketogenic diet (KD) complete meal replacement treatment of obesity-related Type 2 diabetes mellitus (T2DM) and of obesity in patients with obesity and T2DM. This will be an open-label single arm study evaluating glycemic control and weight loss in obese participants with type 2 diabetes treated for 6 months with 3:1 \[fat\]:\[protein+carbohydrate\] ratio, 1600 kcal/day diet.

Treatment will consist of KD complete meal replacement with 3:1 \[fat\]: \[protein + carbohydrate\] weight ratio, and with 1600 kcal restriction. It will consist of pre-made meals, including breakfast, lunch, dinner and two snacks, one each between breakfast and lunch and lunch and dinner. Meals will be made according to supplied recipes (Anemone, LLC.) with a 3-week long meal plan consisting of different recipes for the 3 meals and 2 snacks different for each day of the 3-week cycle, with repeating cycles. All KD-treated participants will receive the same meal plan. Meals will be prepared uniformly by one facility and will be delivered to participants frozen once a week in packages subdivided into individual days with each day's package containing 5 separately packaged meals. Participants will be given a list of allowed 0 calories drinks and will consume no non-allowed beverages. Reductions to oral glycemic medications will occur at the start of the diet.

Participants will be evaluated in face-to-face visit during weeks 1, 2 and 4 of the study, then monthly (see Table 1, visit schedule). Evaluations will include weight, BMI, BP, waist circumference, adverse events and treatment compliance. Participants will check their blood glucose levels 3x/day, including am fasting, mid-day and evening 2 hours post-prandial, and urine for ketones levels with Ketostix (Bayer AG, IN, U.S.A.) 2x/day. They will record results in a glucose and ketone level diary which will be reviewed at each visit. Laboratory evaluations will include 8 am serum fasting glucose, insulin levels, C-peptide and lipid panel, HbA1C, serum beta-hydroxybutyrate (BOH), leptin levels, C-reactive protein (CRP), complete blood count (CBC), basic metabolic profile (BMP), renal and liver functions tests (LFTs), and uric acid. Laboratory evaluations will be obtained once at baseline prior to treatment initiation, at 3 and 6 months after treatment initiation. Hunger will be evaluated with a 7-point Likert scale (range: extremely hungry to extremely full) which will be administered at each visit.
Microcephaly presents heterogeneous genetic etiology linked to several neurodevelopmental disorders (NDD). Copy number variants (CNVs) are a causal mechanism of microcephaly whose investigation is a crucial step for unraveling its molecular basis. Our purpose was to investigate the burden of rare CNVs in microcephalic individuals and to review genes and CNV syndromes associated with microcephaly. We performed chromosomal microarray analysis (CMA) in 185 Brazilian patients with microcephaly and evaluated microcephalic patients carrying < 200 kb CNVs documented in the DECIPHER database. Additionally, we reviewed known genes and CNV syndromes causally linked to microcephaly through the PubMed, OMIM, DECIPHER, and ClinGen databases. Rare clinically relevant CNVs were detected in 39 out of the 185 Brazilian patients investigated by CMA (21%). In 31 among the 60 DECIPHER patients carrying < 200 kb CNVs, at least one known microcephaly gene was observed. Overall, four gene sets implicated in microcephaly were disclosed: known microcephaly genes; genes with supporting evidence of association with microcephaly; known macrocephaly genes; and novel candidates, including OTUD7A, BBC3, CNTN6, and NAA15. In the review, we compiled 957 known microcephaly genes and 58 genomic CNV loci, comprising 13 duplications and 50 deletions, which have already been associated with clinical findings including microcephaly. We reviewed genes and CNV syndromes previously associated with microcephaly, reinforced the high CMA diagnostic yield for this condition, pinpointed novel candidate loci linked to microcephaly deserving further evaluation, and provided a useful resource for future research on the field of neurodevelopment.
BACKGROUND: Prognostic markers for relapse and neurological disability following the first clinical event in children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) remain lacking. We investigated the clinical profiles and early prognostic factors associated with relapsing disease or impaired functional outcome in a large single-center cohort of pediatric MOGAD.
METHODS: We retrospectively analyzed the clinical and paraclinical data and treatment outcomes of children with MOGAD seen at Children's Health in Dallas, Texas from 2009 to 2022. Univariate analyses were used to evaluate factors from initial event associated with relapsing disease course and impaired functional outcome (modified Rankin scale [mRS] >1) at final follow-up.
RESULTS: Our cohort comprised of 87 children of diverse race/ethnicity. Presentation with acute disseminated encephalomyelitis (ADEM) was more frequent in children aged ≤8 years and Caucasian background, whereas presentation with optic neuritis was more common in children aged >8 years and other race/ethnicity. 44.3 % (27/61) had relapsing disease course, of whom 48.0 % had multiple relapses. 30.3 % (23/76) had final mRS >1. Children with abnormal electroencephalogram had reduced relapse risk. Children with ADEM presentation, severe disease, low MOG-IgG titer, and central and systemic inflammation (represented by cerebrospinal fluid pleocytosis and serum leukocytosis, respectively) at onset had higher likelihood of final mRS >1.
CONCLUSION: Abnormal electroencephalogram at the first event was associated with reduced relapse risk while disease severity and peripheral inflammation significantly contributed to final neurological disability. Further studies are needed to validate these findings as early risk factors for disability and relapse and to identify optimal treatment strategies.
PURPOSE: Provided is a new composition comprising liposomes and a polynucleotide which code an immunogenic polypeptide which induces a desired immune response in a human or animal subject. CONSTITUTION: The liposomes comprise cationic components, non-ionic and/or zwitter ionic components which include lipids. The lipids include phospholipids, such as natural or synthetic phosphatidylcholines, phosphatidylethanolamines and phosphatidylserines. The liposomes are made by any of the generally used liposome forming techniques. The liposomes have a mean diameter not exceeding 500 nm, and preferably substantially all have diameters less than 2000 nm. The target tissue for liposome uptake is muscle, skin, liver, spleen cancer cells to be destroyed, such as in the nose or lungs or intestine and especially cells of the lymph nodes. The target cells for gene vaccines are generally antigen presenting cells.
Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia.
This study employs a single group pre-post design to determine the feasibility, safety and efficacy of a 12-week of home-based combined FES and task-specific training program. Also, this study will test the effect of the same intervention on gait, mobility and balance in adults with chronic stroke.
Alzheimer's disease is recognized as a complex condition influenced by multiple factors, necessitating a similarly multifaceted approach to treatment. Ideally, interventions should prioritize averting the progression to dementia. Given the chronic nature of the disease, long-term management strategies are required. Within this framework, lifestyle modifications and dietary supplements emerge as appealing options due to their minimal toxicity, limited side effects, and cost-effectiveness. This study presents findings from a double-blind, placebo-controlled bicentric pilot clinical trial, demonstrating the significant cognitive preservation associated with genistein, a phytoestrogen found in soy and various other dietary sources, among individuals with prodromal Alzheimer's disease. Our prior investigation utilizing APP/PS1 mice elucidated the specific mechanisms through which genistein operates, including anti-amyloid-β, antioxidant, anti-inflammatory, and antiapoptotic effects. These findings underscore the potential of identifying bioactive compounds from dietary sources for the management of Alzheimer's disease.
This project will fully develop and preliminarily validate CampAir, an empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control. In addition to developing a highly novel product for adolescents with asthma, the research proposed for this project will address unique scientific questions. Despite the high asthma prevalence among adolescents, few interventions have specifically targeted adolescents. This study is innovative in that it is among the few to focus on adolescents, who are often overlooked by the healthcare system. This research will assess factors associated with successful implementation of CampAir, thereby providing new information regarding how e-health interventions can be effectively developed and implemented for use with adolescents with asthma. To ensure the software and website function as intended, investigators will systematically test each of the seven CampAir modules with target end users. Participants will review one module per week for seven weeks. As part of each module, participants will also complete a daily asthma checklist. Following the review of each module, participants will be prompted to complete measures assessing technology acceptability and usability and product quality. Results will be used to modify and finalize the user interface and navigation to maximize usability. Results are expected to support that all participants find the CampAir product to be of high quality and technical acceptability. Participants are expected to rate the usability and relevance of the CampAir product highly. All participants are expected to advocate use of the product and recommend continued development and testing.
The present invention provides a multi-component system and a method of making a hypochlorite composition having an increased viscosity and a composition pH of 7 to 12. For example, and preferably, the system and method may be used to provide a (hydro) gel hypochlorite composition. The system or method uses a first amount of a first component comprising a hypochlorite or hypochlorite source having a pH of from 10 to 13.5, preferably 11-13.5, and a separate component comprising a pH-inducing thickener in "dry" form or in dissolved and/or dispersed form at a pH of less than 7. The pH inducing thickener is capable of increasing the viscosity of the composition when subjected to an increased pH, for example, particularly when the composition has a pH of from 7 to 12. Thus, the pH inducing thickener is used to induce a viscosity increase in the hypochlorite composition caused by the alkaline composition pH experienced by the pH inducing thickener. A pH adjuster (acidic or basic) may be present to adjust the pH of the composition to the desired range. The hypochlorite composition may be obtained by combining a certain amount of each component in the system.
Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
PURPOSE: Vascular cognitive impairment(VCI) ranks as the second most prevalent type of dementia.Increasing evidence has shown that inflammation and multi-faceted neuro-immune interactions integrate systemic and central inflammatory pathways, thereby inducing vascular tissue injury and contributing to the development of vascular cognitive impairment (VCI).V-type immunoglobulin-like suppressor of T cell activation (VISTA) is an Negative checkpoint regulators(NCR) that is associated with CNS homeostasis, interactions with peripheral immunity and CNS inflammation.The primary objective of this study was to seek the correlation between VISTA and VCI in patients with cardiovascular risk factors.Our secondary objective was to explore the potential of VISTA as a biomarker for VCI.
PATIENTS AND METHODS: We enrolled individuals with cardiovascular risk factors in this cross-sectional study research and categorized them into two groups: without cognitive impairment (control) and with cognitive impairment (VCI). VISTA expression in peripheral blood mononuclear cells (PBMCs) was analyzed using relative quantitative polymerase chain reaction. VISTA expression was identified in monocyte subsets using flow cytometry. We use Enzyme linked immunosorbent assay to detect inflammatory factors in serum.
RESULTS: In PBMC in patients with VCI, the expression of VSIR was significantly reduced. In contrast to controls, fasting glucose, fibrosis, and the levels of interleukin 6 (IL-6) in VCI patients were noticeably higher, and uric acid levels were significantly lower. Vsir mRNA expression in PBMCs correlated negatively with IL-6 levels, Trail Making Test B scores, and Hachinski scores and positively with Boston Naming Test scores. In intermediate monocytes, flow cytometry showed reduced Vsir expression, which was connected with VCI. The percentage of intermediate monocytes, uric acid, and the VISTA mean fluorescence intensity on intermediate monocytes were shown to be independent factors to VCI by multivariate logistic regression analysis.
CONCLUSION: Decreased VISTA promotes the occurrence of VCI in patients with cardiovascular risk factors by promoting monocytes toward the proinflammatory intermediate monocyte subset. VISTA may serve as a potential biomarker for distinguishing VCI in individuals with cardiovascular risk factors.
The utility model belongs to the technical field of beauty products, particularly relates to wet wipes containing pearl powder, which are used for facial beauty. Two layers of wet wipes are used as supporting materials, and the pearl powder is attached between the two layers of wet wipes. The diameter of the round wet wipes ranges from 20cm to 40cm, and the optimal diameter of the wet wipes is 28cm, and an opening with the length of 5cm is respectively arranged in the middles of the wet wipes. When the wet wipes are applied on the skin, users can feel cool and comfortable, the pearl powder is arranged between the two layers of wet wipes, and effective ingredient of pearls permeates through the wet wipes to be absorbed by the skin, thereby being favorable for exerting efficacy of beauty. The wet wipes containing the pearl powder integrate the effects of the wet wipes and the pearl powder. Pearl medicament exerts effects while the wet wipes are used for cleaning. The pearl powder is arranged between the two layers of wet wipes, thereby avoiding the pearl powder from dropping. The middle opening facilitates breathing, and the surface of the nose is covered completely, using effects are good, and simultaneously the round structure is convenient to carry and use.
PURPOSE:To obtain a high polymer having good long-term stability and useful as a base for pharmaceutical preparations, by treating a specified high polymer with water to remove water-soluble, low-molecular compds. CONSTITUTION:An in-vivo decomposition type high polymer contg. at least 0.01mol (in terms of monobasic acid) of water-soluble, low-molecular compds. per 100g of the polymer is dissolved in an easily water-soluble org. solvent such as acetone in a quantity of 3-20 times (W/V) that of said product to obtain a soln. The soln. is poured into a large excess of water and the mixture is stirred at 0-90 deg.C to obtain an in-vivo decomposition type high (co)polymer which is composed of 50-100mol% of lactic acid and 50-0mol% of glycolic acid, contains less than 0.01mol (in terms of monobasic acid) of the water-soluble, low-molecular compds. per 100g of the polymer and has a weight-average MW of 2,000-50,000 and an intrinsic viscosity of 0.05-0.5dl/g in a 0.5wt% chloroform soln.
The invention relates to the technical field of drug preparations, in particular to a drug composition containing abiraterone acetate, and a preparation method and application of the drug composition.The drug composition is prepared from an active ingredient, namely the abiraterone acetate and accessories including one or more oil phases, one or more emulsifiers and one or more co-emulsifiers. After being orally taken, the drug composition meets gastrointestinal fluid to be spontaneously dispersed under gastrointestinal peristalsis to form O/W-type nanoemulsion. The formed nanoemulsion is small in particle size, the permeability of intestinal epithelial cells is improved, and the bioavailability of drugs can be significantly improved. Compared with microemulsion, a self-emulsified solution has higher stability, and the requirement of long-term preservation can be met. The drug composition is stable in content. Compared with an original drug Zytiga, the difference before and after mealis significantly reduced; and a capsule can be further prepared from the drug composition, and the capsule is stable in property.
The present invention relates to an enteric coated Costus composition with anti-diabetic activity which is enriched with triterpenoids and is made into a dosage form for the treatment of Type-1 and Type-2 diabetes. The Costus Composition is derived from Costus extract derived from Costus plant part. A process of solvent extraction and purification of said extract is also provided. A method for targeted delivery of Costus composition into intestine is provided. A dosage form is provided for the Costus composition. The enrichment with triterpenoids is up to 95% of the composition. Costus composition can lose its activity in acidic condition of the stomach. Hence by giving enteric coating to Costus Composition, it can withstand the acidic condition of the stomach thereby enhancing the bioavailability and bioactivity of the composition.
To achieve maximum contraceptive effectiveness, PIMTREA™ (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets must be taken exactly as directed and at intervals not exceeding 24 hours. PIMTREA™ may be initiated using either a Sunday start or a Day 1 start.

NOTE: Each cycle pack dispenser is preprinted with the days of the week, starting with Sunday, to facilitate a Sunday start regimen. Six different "day label strips" are provided with each cycle pack dispenser in order to accommodate a Day 1 start regimen. In this case, the patient should place the self-adhesive "day label strip" that corresponds to her starting day over the preprinted days.

IMPORTANT: The possibility of ovulation and conception prior to initiation of use of PIMTREA™ should be considered.

The use of PIMTREA™ for contraception may be initiated 4 weeks postpartum in women who elect not to breast feed. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (see CONTRAINDICATIONS and WARNINGS concerning thromboembolic disease. See also PRECAUTIONS for "Nursing Mothers").

If the patient starts on PIMTREA™ postpartum, and has not yet had a period, she should be instructed to use another method of contraception until a dark blue tablet has been taken daily for 7 days.
Inflammation is a ubiquitous physiological status that exists during the occurrence, development and prognosis of numerous diseases. Clinical anti-inflammatory drugs mainly include antibiotics, antivirals, non-steroids and corticosteroids, and the treatments are often accompanied by side effects, including nausea, abdominal pain, allergy, nerve injury and organ dysfunction. Current studies have focused on continuously exploring efficient anti-inflammatory natural components with high biosafety, while nisin, a natural bioactive anti-microbial peptide produced by Lactococcus, has been reported to have anti-inflammatory activity via its superior anti-bacterial abilities. Several recent studies have focused on the potent direct anti-inflammation of nisin, whereas its effects and the corresponding mechanism still remain unclear. The cellular and Caenorhabditis elegans (C. elegans) models were constructed in this study to evaluate the anti-inflammatory effects of nisin A both in vitro and in vivo, while the inflammatory mechanism was further uncovered based on omics analysis. This study reveals the direct anti-inflammatory activity of nisin A and elucidates the regulatory actions of nisin A on adenosine, followed by alteration of the sphingolipid signaling pathway and purine metabolism, enhancing the deep understanding of nisin A with its anti-inflammatory capacity, providing new ideas for future nisin A-based anti-inflammatory strategies.
HOPE18 will be an open label, 2-arm study of HU disposition in 48 children with SCD. In Arm 1, n=18 infants ages 9 months to 2 years will be administered an extemporaneous oral liquid formulation of HU on a single occasion followed by PK sampling. The dose administered will be \~20 mg/kg/day or the infant's usual daily dose. In Arm 2, n=30 children who range in age from 2 to 18 years will be administered HU, both a sprinkle formulation and capsules (Droxia® 200 mg), on two separate occasions separated by at least 1 day but no more than 30 days in a randomized, crossover fashion. The doses of HU on each occasion will be rounded to the nearest 200 mg and will not exceed 35 mg/kg or 2000 mg. We hypothesize that the PK profile of the sprinkle formulation will not differ significantly from the PK profile of Droxia® capsules in children and adolescents ages ≥2 - 18 years of age. Participants in both arms will be followed up to 30 days from receiving last HU dose.
The participants will receive cannabis product for 2 weeks. The participants will receive the cannabis product (THC 30mg / 1 ml) manufactured by Faculty of pharmaceutical science KhonKaen University. The participants will gradually increase using the product starting from 1 drop (1.5 mg THC) per day sublingually and can increase using not more than 1 drop per day, until pain or spasticity can be controlled.
This study is a 3+3 dose escalation design. Participants will receive a total of 6 cycles of SW1115C3 every 21 days.